Diabetic ketoacidosis (DKA) is the most common acute complication and leading cause of mortality in children and adolescents with diabetes. While DKA is mainly seen in type 1 diabetes, youth with type 2 diabetes, especially adolescents, are also susceptible to this condition. As a standard of care, individuals at risk for DKA and their caregivers are provided with instructions for preventing and managing ketone development. However, the use of urine ketone or blood ketone monitoring is often suboptimal. Abbott Diabetes Care (Alameda, CA) is developing a dual monitoring system that continuously measures interstitial glucose and β-hydroxybutyrate using a single continuous dual glucose–ketone (DGK) sensor. The use of continuous ketone monitors in the pediatric population has the potential to improve at-home monitoring and early initiation of intervention with rising ketone levels prior to severe DKA requiring hospitalization. This article reviews the importance of ketone testing, examines current testing options, and discusses how DGK, a novel testing technology, can reduce the occurrence of DKA in children and adolescents who are living with diabetes.
WardZJ, YehJM, ReddyCL, et al.Estimating the total incidence of type 1 diabetes in children and adolescents aged 0-19 years from 1990 to 2050: A global simulation-based analysis. Lancet Diabetes Endocrinol, 2022; 10(12):848–858; doi: 10.1016/S2213-8587(22)00276-5
2.
WuH, PattersonCC, ZhangX, et al.Worldwide estimates of incidence of type 2 diabetes in children and adolescents in 2021. Diabetes Res Clin Pract, 2022; 185:109785; doi: 10.1016/j.diabres.2022.109785
3.
InselRA, DunneJL, AtkinsonMA, et al.Staging presymptomatic type 1 diabetes: A scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care, 2015; 38(10):1964–1974.
4.
Foti RandazzeseS, La RoccaM, BombaciB, et al.Severe diabetic ketoacidosis in children with type 1 diabetes: Ongoing challenges in care. Children (Basel), 2025; 12(1):110; doi: 10.3390/children12010110
KitabchiAE, UmpierrezGE, MurphyMB, KreisbergRA. Hyperglycemic crises in adult patients with diabetes: A consensus statement from the American Diabetes Association. Diabetes Care, 2006; 29(12):2739–2748; doi: 10.2337/dc06-9916
7.
Albanese-O’NeillA, WuM, MillerKM, et al.; T1D Exchange Clinic Network. Poor adherence to ketone testing in patients with type 1 diabetes. Diabetes Care, 2017; 40(4):e38–e39; doi: 10.2337/dc16-2620
8.
DabeleaD, RewersA, StaffordJM, et al.; SEARCH for Diabetes in Youth Study Group. Trends in the prevalence of ketoacidosis at diabetes diagnosis: The SEARCH for diabetes in youth study. Pediatrics, 2014; 133(4):e938–e945.
9.
WolfsdorfJI, GlaserN, AgusM, et al.ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Pediatr Diabetes, 2018; 19(Suppl 27):155–177; doi: 10.1111/pedi.12701
10.
ZeitlerP, ArslanianS, FuJ, et al.ISPAD clinical practice consensus guidelines 2018: Type 2 diabetes mellitus in youth. Pediatr Diabetes, 2018; 19(Suppl 27):28–46; doi: 10.1111/pedi.12719
11.
PoovazhagiV. Risk factors for mortality in children with diabetic keto acidosis from developing countries. World J Diabetes, 2014; 5(6):932–938; doi: 10.4239/wjd.v5.i6.932
12.
PraveenPA, HockettCW, OngTC, et al.Diabetic ketoacidosis at diagnosis among youth with type 1 and type 2 diabetes: Results from SEARCH (United States) and YDR (India) registries. Pediatr Diabetes, 2021; 22(1):40–46; doi: 10.1111/pedi.12979
13.
RaghupathyP. Diabetic ketoacidosis in children and adolescents. Indian J Endocrinol Metab, 2015; 19(Suppl 1):S55–S7; doi: 10.4103/2230-8210.155403
14.
KlingensmithGJ, ConnorCG, RuedyKJ, et al.; Pediatric Diabetes Consortium. Presentation of youth with type 2 diabetes in the Pediatric Diabetes Consortium. Pediatr Diabetes, 2016; 17(4):266–273; doi: 10.1111/pedi.12281
15.
CherubiniV, GrimsmannJM, ÅkessonK, et al.Temporal trends in diabetic ketoacidosis at diagnosis of pediatric type 1 diabetes between 2006 and 2016: Results from 13 countries in three conti- nents. Diabetologia, 2020; 63(8):1530–1541.
16.
JensenET, StaffordJE, SaydahS, et al.Increase in prevalence of diabetic ketoacidosis at diagnosis among youth with type 1 diabetes: The SEARCH for diabetes in youth study. Diabetes Care, 2021; 44(7):1573–1578; doi: 10.2337/dc20-0389
17.
ManuwaldU, SchofferO, HegewaldJ, et al.Ketoacidosis at onset of type 1 diabetes in children up to 14 years of age and the changes over a period of 18 years in Saxony, eastern-Germany: A population based register study. PLoS One, 2019; 14(6):e0218807; doi: 10.1371/journal.pone.0218807
18.
RahmatiM, KeshvariM, MirnasuriS, et al.The global impact of COVID-19 pandemic on the incidence of pediatric new-onset type 1 diabetes and ketoacidosis: A systematic review and meta-analysis. J Med Virol, 2022; 94(11):5112–5127; doi: 10.1002/jmv.27996
19.
BombaciB, PassanisiS, SorrentiL, et al.Examining the associations between COVID-19 infection and pediatric type 1 diabetes. Expert Rev Clin Immunol, 2023; 19(5):489–497; doi: 10.1080/1744666X.2023.2189587
20.
GottesmanBL, YuJ, TanakaC, et al.Incidence of new-onset type 1 diabetes among US children during the COVID-19 global pandemic. JAMA Pediatr, 2022; 176(4):414–415; doi: 10.1001/jamapediatrics.2021.5801
21.
MaahsDM, HermannJM, HolmanN, et al.; National Paediatric Diabetes Audit and Royal College of Paediatrics and Child Health; DPV Initiative; T1D Exchange Clinic Network. Rates of diabetic ketoacidosis: International comparison with 49,859 pediatric patients with type 1 diabe- tes from England, Wales, the U.S., Austria, and Germany. Diabetes Care, 2015; 38(10):1876–1882; doi: 10.2337/dc15-0780
22.
TiederJS, McLeodL, KerenR, et al.; Pediatric Research in Inpatient Settings Network. Variation in resource use and readmission for diabetic ketoacidosis in children’s hospitals. Pediatrics, 2013; 132(2):229–236.
23.
LiuCC, ChenKR, ChenHF, et al.Trends in hospitalization for diabetic ketoacidosis in diabetic patients in Taiwan: Analysis of national claims data, 1997–2005. J Formos Med Assoc, 2010; 109(10):725–734; doi: 10.1016/S0929-6646(10)60117-9
24.
NyenweE, LoganathanR, BlumS, et al.Admissions for diabetic ketoacidosis in ethnic minority groups in a city hospital. Metabolism, 2007; 56(2):172–178; doi: 10.1016/j.metabol.2006.09.010
25.
HammersenJ, TittelSR, WarnckeK, et al.; DPV Initiative. Previous diabetic ketoacidosis as a risk factor for recurrence in a large prospective contemporary pediatric cohort: Results from the DPV initiative. Pediatr Diabetes, 2021; 22(3):455–462; doi: 10.1111/pedi.13185
26.
GibbFW, TeohWL, GrahamJ, LockmanKA. Risk of death following admission to a UK hospital with diabetic ketoacidosis. Diabetologia, 2016; 59(10):2082–2087; doi: 10.1007/s00125-016-4034-0
GarrettCJ, ChoudharyP, AmielSA, et al.Recurrent diabetic ketoacidosis and a brief history of brittle diabetes research: Contemporary and past evidence in diabetic ketoacidosis research including mortality, mental health and prevention. Diabet Med, 2019; 36(11):1329–1335; doi: 10.1111/dme.14109
29.
RamaeshA. Incidence and long-term outcomes of adult patients with diabetic ketoacidosis admitted to intensive care: A retrospective cohort study. J Intensive Care Soc, 2016; 17(3):222–233; doi: 10.1177/1751143716644458
30.
KostopoulouE, SinopidisX, FouzasS, et al.Diabetic ketoacidosis in children and adolescents; diagnostic and therapeutic pitfalls. Diagnostics (Basel), 2023; 13(15):2602; doi: 10.3390/diagnostics13152602
31.
VirdiN, PoonY, AbanielR, BergenstalRM. Prevalence, cost, and burden of diabetic ketoacidosis. Diabetes Technol Ther, 2023; 25(S3):S75–S84; doi: 10.1089/dia.2023.0149
32.
EdgeJA, HawkinsMM, WinterDL, DungerDB. The risk and outcome of cerebral oedema developing during diabetic ketoacidosis. Arch Dis Child, 2001; 85(1):16–22. http://www.ncbi.nlm.nih.gov/pubmed/11420189
33.
GlaserN, BarnettP, McCaslinI, et al.; Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. Risk factors for cerebral edema in children with diabetic ketoacidosis. the pediatric emergency medicine collaborative research committee of the american academy of pediatrics. N Engl J Med, 2001; 344(4):264–269; doi: 10.1056/NEJM200101253440404
34.
DucaLM, WangB, RewersM, RewersA. Diabetic ketoacidosis at diagnosis of type 1 diabetes predicts poor long-term glycemic control. Diabetes Care, 2017; 40(9):1249–1255; doi: 10.2337/dc17-0558
35.
ShalitinS, FisherS, Yackbovitch-GavanM, et al.Ketoacidosis at onset of type 1 diabetes is a predictor of long-term glycemic control. Pediatr Diabetes, 2018; 19(2):320–328; doi: 10.1111/pedi.12546
36.
AyeT, MazaikaPK, MaurasN, et al.; Diabetes Research in Children Network (DirecNet) Study Group. Impact of early diabetic ketoacidosis on the developing brain. Diabetes Care, 2019; 42(3):443–449; doi: 10.2337/dc18-1405
37.
JaserSS, JordanLC. Brain health in children with type 1 diabetes: Risk and protective factors. Curr Diab Rep, 2021; 21(4):12; doi: 10.1007/s11892-021-01380-w
38.
EL-MohandesN, YeeG, BhuttaBS, et al.Pediatric Diabetic Ketoacidosis. In: StatPearls. StatPearls Publishing: Treasure Island, FL; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470282/#
39.
AkturkHK, Snell-BergeonJ, PyleL, et al.Accuracy of a breath ketone analyzer to detect ketosis in adults and children with type 1 diabetes. J Diabetes Complications, 2021; 35(11):108030.
DhatariyaK. Blood ketones: Measurement, interpretation, limitations, and utility in the management of diabetic ketoacidosis. Rev Diabet Stud, 2016; 13(4):217–225; doi: 10.1900/RDS.2016.13.217
42.
MooreAR, Holland-WinklerAM, AnsleyJK, et al.Reliability and diagnostic performance of a new blood ketone and glucose meter in humans. J Int Soc Sports Nutr, 2021; 18(1):6; doi: 10.1186/s12970-020-00404-2
43.
LaffelLM, WentzellK, LoughlinC, et al.Sick day management using blood 3-hydroxybutyrate (3-OHB) compared with urine ketone monitoring reduces hospital visits in young people with T1DM: A randomized clinical trial. Diabet Med, 2006; 23(3):278–284; doi: 10.1111/j.1464-5491.2005.01771.x
44.
PhelanH, HanasR, HoferSE, et al.Sick day management in children and adolescents with diabetes. Pediatr Diabetes, 2022; 23(7):912–925; doi: 10.1111/pedi.13415
45.
AlvaS, CastorinoK, ChoH, OuJ. Feasibility of continuous ketone monitoring in subcutaneous tissue using a ketone sensor. J Diabetes Sci Technol, 2021; 15(4):768–774; doi: 10.1177/19322968211008185
46.
HarrisMA, WagnerDV, WilsonAC, et al.Novel interventions in children’s healthcare for youth hospitalized for chronic pain. Clin Pract Pediatr Psychol, 2015; 3(1):48–58; doi: 10.1037/cpp0000088
47.
Orsini-FedericiM, AkwiJA, CanonicoV, et al.Early detection of insulin deprivation in continuous subcutaneous insulin infusion-treated patients with type 1 diabetes. Diabetes Technol Ther, 2006; 8(1):67–75; doi: 10.1089/dia.2006.8.67
48.
DavisGM, HughesMS, BrownSA, et al.Automated insulin delivery with remote real-time continuous glucose monitoring for hospitalized patients with diabetes: A multicenter, single-arm, feasibility trial. Diabetes Technol Ther, 2023; 25(10):677–688; doi: 10.1089/dia.2023.0304
49.
KlonoffDC, AyersAT, HoCN, et al.Time to moderate and severe hyperglycemia and ketonemia following an insulin pump occlusion. J Diabetes Sci Technol, 2024; 18(6):1472–1479; doi: 10.1177/19322968241280386Erratum in: J Diabetes Sci Technol. 2025 Mar 13:19322968251325907. 10.1177/19322968251325907
50.
BiesterT, BergetC, BoughtonC, et al.International society for pediatric and adolescent diabetes clinical practice consensus guidelines 2024: Diabetes technologies – insulin delivery. Horm Res Paediatr, 2024; 97(6):636–662; doi: 10.1159/000543034
51.
EkhlaspourL, TownM, RaghinaruD, et al.Glycemic outcomes in baseline hemoglobin A1C subgroups in the international diabetes closed-loop trial. Diabetes Technol Ther, 2022; 24(8):588–591; doi: 10.1089/dia.2021.0524
52.
PlewaMC, BryantM, King-ThieleR. Euglycemic Diabetic Ketoacidosis. In: StatPearls. StatPearls Publishing: Treasure Island, FL; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554570/
53.
PetersAL, BuschurEO, BuseJB, et al.Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care, 2015; 38(9):1687–1693; doi: 10.2337/dc15-0843
54.
RawlaP, VellipuramAR, BandaruSS, Pradeep RajJ. Euglycemic diabetic ketoacidosis: A diagnostic and therapeutic dilemma. Endocrinol Diabetes Metab Case Rep, 2017; 2017:17; doi: 10.1530/EDM-17-0081
55.
PhungK, HendersonM, GeoffroyL. First case report of euglycemic diabetic ketoacidosis with an automated insulin pump in a 12-year-old patient with type 1 diabetes mellitus. Can J Diabetes, 2022; 46(1):81–83; doi: 10.1016/j.jcjd.2021.05.008
56.
ThompsonBD, KitchenA. Euglycemic diabetic ketoacidosis in type 1 diabetes on insulin pump, with acute appendicitis: A case report. Clin Pract Cases Emerg Med, 2021; 5(3):136–138; doi: 10.5811/cpcem.2021.1.48905
57.
GargSK, KaurG, HaiderZ, et al.Efficacy of semaglutide in overweight and obese patients with type 1 diabetes. Diabetes Technol Ther, 2024; 26(3):184–189; doi: 10.1089/dia.2023.0490
58.
Snell-BergeonJK, KaurG, RennerD, et al.Effectiveness of semaglutide and tirzepatide in overweight and obese adults with type 1 diabetes. Diabetes Technol Ther, 2025; 27(1):1–9; doi: 10.1089/dia.2024.0328
59.
MooreDJ, LeibelNI, PolonskyW, RodriguezH. Recommendations for screening and monitoring the stages of type 1 diabetes in the immune therapy era. Int J Gen Med, 2024; 17:3003–3014; doi: 10.2147/IJGM.S438009
60.
KongYW, MorrisonD, LuJC, et al.Continuous ketone monitoring: Exciting implications for clinical practice. Diabetes Obes Metab, 2024; 26(Suppl 7):47–58; doi: 10.1111/dom.15921
